Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Keytruda
Keytruda
The end of the Humira era
EP Vantage
Mon, 01/30/23 - 10:46 am
AbbVie
Humira
patents
biosimilars
Merck
Keytruda
A Hit and a Miss for Merck’s Keytruda
BioSpace
Wed, 01/25/23 - 10:42 am
Merck
Keytruda
prostate cancer
biliary tract cancer
Immuno-oncology goes subcutaneous
EP Vantage
Wed, 01/25/23 - 10:18 am
immuno-oncology
oncology
subcutaneous drug delivery
Keytruda
Merck
Tecentriq
Roche
Chasing Roche, Merck talks up subcutaneous Keytruda ahead of phase 3 data drop
Fierce Pharma
Mon, 01/16/23 - 11:16 am
Merck
Keytruda
Roche
cancer
oncology
BioXcel, keeping cards close to its chest, teases phase 2 Keytruda combination trial data drop
Fierce Biotech
Wed, 01/11/23 - 11:00 am
BioXcel Therapeutics
clinical trials
Keytruda
BXCL701
prostate cancer
Merck Highlights Growth Strategy at J.P. Morgan
BioSpace
Tue, 01/10/23 - 06:48 pm
Merck
JPMHC 2023
Keytruda
vaccines
M&A
OncoC4 doses first participant in ovarian cancer therapy trial
Clinical Trials Arena
Mon, 01/2/23 - 06:33 pm
OncoC4
clinical trials
ONC-392
Merck
Keytruda
ovarian cancer
platinum-resistant ovarian cancer
Moderna, Merck & Co. mRNA cancer vaccine slashes melanoma recurrence in Keytruda combo trial
Fierce Biotech
Tue, 12/13/22 - 10:35 am
Merck
Moderna Therapeutics
MRNA
cancer immunotherapy
Keytruda
melanoma
Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients
Yahoo/Reuters
Tue, 12/6/22 - 10:21 am
Mirati Therapeutics
adagrasib
Merck
Keytruda
metastatic lung cancer
lung cancer
GSK unveils Keytruda head-to-head data in lung cancer—and they look good at first glance
Fierce Pharma
Wed, 11/30/22 - 07:58 pm
GSK
Merck
Jemperli
Keytruda
clinical trials
non-small cell lung cancer
Merck scores another win for Keytruda, this time in HER2-negative cancer
Endpoints
Tue, 11/22/22 - 04:39 pm
Merck
Keytruda
clinical trials
adenocarcinoma
Is Merck Too Dependent on Keytruda?
Motley Fool
Wed, 11/9/22 - 10:50 am
Merck
Keytruda
Catching up with Keytruda, Regeneron scores frontline NSCLC approval for Libtayo/chemo combo
Endpoints
Wed, 11/9/22 - 10:38 am
Regeneron
Libtayo
non-small cell lung cancer
Keytruda
Merck
Gilead, Arcus slim phase 3 TIGIT trial to take on king Keytruda
Fierce Biotech
Thu, 11/3/22 - 11:10 am
Gilead Sciences
ARCUS
clinical trials
Merck
Keytruda
domvanalimab
zimberelimab
non-small cell lung cancer
Bristol Myers spells out Opdivo win in melanoma — how does it stack up against Keytruda?
Endpoints
Thu, 10/20/22 - 10:41 am
Bristol Myers Squibb
Opdivo
melanoma
Merck
Keytruda
Kineta, Merck Strike Deal to Pair Anti-VISTA Antibody with Keytruda
BioSpace
Mon, 10/17/22 - 10:51 am
Kineta
Merck
Keytruda
anti-VISTA
monoclonal antibodies
solid tumors
OncoSec sheds 45% of staff to fund IL-12 drug through Keytruda combo trial
Fierce Biotech
Wed, 10/5/22 - 10:31 am
OncoSec Medical
melanoma
clinical trials
Keytruda
layoffs
Tavo
Keytruda taught Merck how to build a blockbuster. But manufacturing a 2nd lightning bolt is easier said than done
Fierce Pharma
Thu, 09/29/22 - 07:42 pm
Merck
Keytruda
cancer
oncology
ESMO
Bristol Myers' Opdivo win tees up showdown with Keytruda in earlier-stage melanoma
Fierce Pharma
Thu, 09/15/22 - 11:15 pm
Merck
Keytruda
Bristol Myers Squibb
Opdivo
melanoma
ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?
Fierce Pharma
Mon, 09/12/22 - 10:57 am
ESMO
Roche
Bristol Myers Squibb
kidney cancer
Keytruda
Merck
Opdivo
Yervoy
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »